688621.SH
阳光诺和
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 65.00
−1.53%Year over year
Reported trailing growth
- Revenue
- +12.4%
- EBITDA
- —
- EBIT
- +62.6%
- EPS
- +46.5%
- Free cash flow
- —
- Operating cash flow
- -77.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +21.8%
- EBITDA
- +9.2%
- EBIT
- +7.8%
- Net income
- +9.2%
- EPS
- +9.9%
- Free cash flow
- +720.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026